medigraphic.com
ISSN 1561-3186 (Electronic)

2015, Number 1

<< Back Next >>

Rev Acta Médica 2015; 16 (1)

Niveles de hemoglobina glucosilada y su correlación con las glucemias de ayuno y postprandial en un grupo de pacientes diabéticos

Rodríguez AL, Sosa PJC, Buchaca FEF, Fernández VF, Bermúdez RSA, Mora I

Language: Spanish
References: 54
Page:
PDF size: 256.93 Kb.


ABSTRACT

No abstract.


REFERENCES

  1. White F. La importancia del consenso en la prevención y el control de la diabetes en América Latina y el Caribe. Visión Méd. 1997;20:13-6.

  2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates and projections. Diabetes Care. 1998;21:1414-31.

  3. International Diabetes Federation. Atlas of diabetes extract [Internet]. 2003 [cited 2014 Nov 14]. Available from: http://www.eatlas.idf.org/media

  4. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047- 53.

  5. Pirat J. Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947 and 1973. Diabetes Care. 1978;1:168-88;252- 63.

  6. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.

  7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-53.

  8. UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS35). BMJ. 2000;321:405- 12.

  9. Effect of intensive diabetes management on macrovascular events and risk factors in the diabetes control and complications trial. Am J Cardiol 1995;75:894-903.

  10. Turner RC. The U.K. prospective diabetes study. A review. Diabetes Care. 1998;21(Suppl 3):C35-8.

  11. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2000;23(Suppl 1):S32-42.

  12. Standards of medical care in diabetes. Diabetes Care 2005;28(Suppl 1):S4-S36.

  13. Standards of medical care in diabetes-2007. Diabetes Care 2007;30(Suppl 1):S4- S41.

  14. Standards of medical care in diabetes-2008. Diabetes Care 2008;31(Suppl 1):S12- 54.

  15. Actis SM, Rebolledo OR. La glicación y glicooxidación de las lipoproteínas. Su importancia en la diabetes mellitus. Rev Med Buenos Aires. 2000;60:645-6.

  16. Lim HS. Fructosamine and diabetes. Singapore Med J 1988;29:541-3.

  17. Sera RA, García M, Moreira R. Glicación de proteínas como elemento esencial en las complicaciones crónicas de la diabetes mellitus. Rev Cis Méd Hab. 2001;7:1-9.

  18. Setter SM. Biochemical pathways for microvascular complications of diabetes mellitus. Ann Pharmacother. 2003;37:1858-66.

  19. Kalousova M, Zima T, Tesar V, Dusilova-Sulkova S, Skrha J. Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat Res. 2005;579:37-46.

  20. Valdiguié P. Fisiopatología de las complicaciones reumatológicas de la diabetes. L´Observatoire du Mouvement. 2006;7:1-3.

  21. Youssef D, El Abbassi A, Jordan RM, Peiris AN. Fructosamine-an underutilized tool in diabetes management: case report and literature review. Tenn Med. 2008;101:31-3.

  22. Soca PEM, Bahr AP, Niño S. Mecanismos moleculares del daño microvascular de la diabetes mellitus. Correo Cientif Méd Hol. 2004;8:1-11.

  23. Obregón O, Vecchionacce H, Brito S, Lares M, Castro J, Ramírez X, et al. Efecto antiglicosilante de las vitaminas E y C. Arch Venez Farmacol Terap. 2005;24:1-10.

  24. Gebel E. A hypothesis for the AGEs. Exploring the link between high blood glucose and diabetes complications. Diabetes Forescast. 2010;63:52-5.

  25. Méndez JD, Xie J, Aguilar M, Méndez V. Trends in advanced glycation end products research in diabetes mellitus and its complications. Mol Cell Biochem [Internet]. 2010 [cited 2014 Nov 14]. Available from:http://www.springerlink.com/content/wmg173j7w459u483/

  26. Jenkins M, Ratnaike S. Capillary electrophoresis of hemoglobin. Clin Chem Lab Med. 2003;41:747-54.

  27. Iglesias P, Díez JJ. Glucación no enzimática de proteínas en la diabetes mellitus. Med Clin (Barc). 1997;108:23-33.

  28. Fitzgibbons JF, Koler RD, Jones RT. Red-cell age-related changes of hemoglobins AIa+b and AIc in normal and diabetic subjects. J Clin Invest 1976;41:820-4.

  29. Bunn HF, Haney DN, Kamin S, Gabbay KH, Gallop PM. The biosynthesis of human hemoglobin A1c. Slow glycosylation of hemoglobin in vivo. J Clin Invest 1976;57:1652- 9.

  30. Goldstein DE, Little RR, Wiedmeyer HM, et al. Glycated hemoglobin: methodologies and clinical applications. Clin Chem 1986;32(10 Suppl):B64-70.

  31. Gonen B, Rubenstein A, Rochman H, Tanega SP, Horwitz DL. Haemoglobin A1: an indicator of the metabolic control of diabetic patients. Lancet 1977;2:734-7.

  32. Davis JE, McDonald JM, Jarett L. A high-performance liquid chromatography method for hemoglobin A1c. Diabetes 1978;27:102-7.

  33. Beccaria L, Chiumello G, Gianazza E, Luppis B, Righetti PG. Hemoglobin A1C separation by isoelectric focusing. Am J Hematol 1978;4:367-74.

  34. Poynard JP, Malgrange D, Couchot J, Caron J, Leutenegger M, Maquart FX, et al. Dosage par micromethode de l’hemoglobine A1c chez les diabetiques. Premiers resultats. Nouv Presse Med 1978;7:1648-9.

  35. Ezcurra EJ. Montaje y estandarización de la determinación calorimétrica de hemoglobina glicosilada. Rev Cubana Med. 1986;25:660-6.

  36. Ezcurra EJ. La hemoglobina glicosilada y su importancia en la práctica asistencial e investigativa en el campo de la diabetes mellitus. Revisión bibliográfica. Rev Cubana Med. 1986;25:592-602.

  37. Fuscaldo C, Calzada L, Estrada Y, Salazar S, Monge S, Artavia E, Figueroa V et al. La calidad del control del paciente diabético en Costa Rica. AMC 2000;42:205.

  38. Eschwege E. Epidemiology of type II diabetes, diagnosis, prevalence, risk factors, complications. Arch Mal Coeur Vaiss. 2000;93(4):13-1.

  39. Anuario estadístico de Cuba 2008. La Habana: Oficina Nacional de Estadísticas; 2008. Disponible en: http://www.one.cu/aec2008/datos/19.18.xls

  40. Rodríguez A, Álvarez L. Repercusiones del envejecimiento de la población cubana en el sector salud. Rev Cubana Salud Púb. 2006;32:178-82.

  41. Cooper RS, Orduñez P, Iraola MD, Bernal JL, Espinosa-Brito A. Cardiovascular disease and associated risk factors in Cuba: prospects for prevention and control. Am J Public Health. 2006;96:94-101.

  42. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care. 1998;21:1414-31.

  43. Pani LN, Korenda L, Meigs JB, Driver C, Chamany S, Fox CS, et al. Effect of aging on A1c levels in individuals without diabetes: evidence from the framingham offspring study and the national health and nutrition examination survey 2001-2004. Diabetes Care. 2008;31:1991-6.

  44. Seuc AH, Domínguez E, Díaz O. Esperanza de vida ajustada por diabetes. Rev Cubana Endocrinol [Internet]. 2003 [citado 14 Nov 2014];14(3). Disponible en: http://scieloprueba.sld.cu/scielo.php?script=sci_arttext&pid=S1561- 30032005000200006&lng=es&nrm=iso

  45. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care. 2008;31(Suppl 1):S12-54.

  46. American Diabetes Association: Standards of medical care in diabetes 2012 (Position Statement). Diabetes Care 35(Suppl 1):S76-S80.

  47. Ezcurra Ferrer EJ. Correlación entre niveles glicémicos y concentración de hemoglobina glicosilada en pacientes diabéticos. Rev Cubana Med 1986;25(11):1104- 10.

  48. Buse JB, Hroscikoski M. The case for a role for postprandial glucose monitoring in diabetes management. J Fam Pract. 1998 Nov;47(5 Suppl)S29-36. PMID: 9834753.

  49. International Diabetes Federation. Clinical Guidelines Task Force. Guía global para la diabetes tipo 2. Bruselas [Internet]. 2006 [citado 14 Nov 2014]. Disponible en: http://www.idf.org/webdata/docs/GGTD%20Spanish%20Fi

  50. Asociación Latinoamericana de Diabetes. Guías ALAD de diagnóstico, control y tratamiento de la diabetes mellitus tipo 2[Internet]. Washington DC: Organización Panamericana de la Salud; 2007 [citado 14 Nov 2014]. Disponible en: www.paho.org/mex/index.php?option=com_docman&task

  51. National Collaborating Centre for Chronic Conditions.Type 2 diabetes: National clinical guideline for management in primary and secondary care (update) [Internet]. London: Royal College of Physicians; 2008 [cited 2014 Nov 14]. Disponible en: http://www.nice.org.uk

  52. Committee. Canadian D iabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes. 2008;32(suppl 1):1-201.

  53. Documento 2005 de consenso entre varias sociedades científicas sobre pautas de manejo del paciente diabético tipo 2 en España. Av Diabetol [Internet]. 2005 [citado 14 Nov 2014];21(S1). Disponible en:www.sediabetes.org/gestor/upload/revistaAvances/21-supl-1.pdf

  54. El-Kebbi IM, Ziemer DC, Gallina DL, Phillips LS. Diabetes in urban africanamericans VI. Utility of fasting or random glucose in identifying poor glycemic control. Diabetes Care 1998;21:501-5.




2020     |     www.medigraphic.com